EXOC2

Summary

EXOC2 (exocyst complex component 2, HGNC:24968) is a protein-coding gene on chromosome 6p25.3, encoding Exocyst complex component 2 (Q96KP1). Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. It is a selective cancer dependency (DepMap: 27.1% of cell lines).

The protein encoded by this gene is a component of the exocyst complex, a multi-protein complex essential for the polarized targeting of exocytic vesicles to specific docking sites on the plasma membrane. Though best characterized in yeast, the component proteins and the functions of the exocyst complex have been demonstrated to be highly conserved in higher eukaryotes. At least eight components of the exocyst complex, including this protein, are found to interact with the actin cytoskeletal remodeling and vesicle transport machinery. This interaction has been shown to mediate filopodia formation in fibroblasts. This protein has been shown to interact with the Ral subfamily of GTPases and thereby mediate exocytosis by tethering vesicles to the plasma membrane. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55770 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 61 (top 1% of genes corpus-wide)
• Clinical variants (ClinVar): 252 total — 4 pathogenic
• GTEx eGene: eQTL in 46 tissues, sQTL in 23 (q < 0.05)
• Phenotypes (HPO): 37
• Cancer dependency (DepMap): dependent in 27.1% of screened cell lines
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.63 (unconstrained)
• MANE Select transcript: NM_018303
• Notable: 252 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24968
Approved symbol	EXOC2
Name	exocyst complex component 2
Location	6p25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11026, Sec5
Ensembl gene	ENSG00000112685
Ensembl biotype	protein_coding
OMIM	615329
Entrez	55770

Gene structure

Transcript identifiers

Ensembl transcripts: 40 — 35 protein_coding, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000230449

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 3: 1, TSL 4: 1

ENST00000230449, ENST00000443083, ENST00000475028, ENST00000870874, ENST00000870875, ENST00000870876, ENST00000870877, ENST00000870878, ENST00000870879, ENST00000930287, ENST00000930288, ENST00000930289, ENST00000930290, ENST00000930291, ENST00000930292, ENST00000930293, ENST00000930294, ENST00000930295, ENST00000930296, ENST00000949686, ENST00000949687, ENST00000949688, ENST00000949689, ENST00000949690, ENST00000949691, ENST00000949692, ENST00001001316, ENST00001001317, ENST00001001318, ENST00001023356, ENST00001082419, ENST00001111283, ENST00001113899, ENST00001113900, ENST00001113901, ENST00001113902, ENST00001113903, ENST00001113904, ENST00001113905, ENST00001135574

RefSeq mRNA: 1 — MANE Select: NM_018303 NM_018303

CCDS: CCDS34327

Canonical transcript exons

ENST00000230449 — 28 exons

Exon	Start	End
ENSE00000679928	637701	637861
ENSE00000847761	632941	633117
ENSE00001275977	485154	486764
ENSE00001961245	592469	592587
ENSE00001962595	572520	572644
ENSE00001963937	610098	610178
ENSE00001964901	564033	564154
ENSE00001966837	617711	617835
ENSE00001968959	549175	549291
ENSE00001970714	488979	489038
ENSE00001971092	562784	562845
ENSE00001971333	499645	499700
ENSE00001975259	532469	532610
ENSE00001976768	564864	564929
ENSE00001977261	555954	556013
ENSE00001977911	619430	619543
ENSE00001978306	556484	556564
ENSE00001979168	491125	491186
ENSE00001979195	598021	598123
ENSE00001983308	564545	564702
ENSE00001983943	555227	555288
ENSE00001985443	553854	553920
ENSE00001986055	497367	497489
ENSE00001987451	599080	599225
ENSE00001988149	598860	598941
ENSE00003643190	576757	576882
ENSE00003789881	629835	629961
ENSE00003846072	693019	693139

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 90.57.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.4902 / max 112.4891, expressed in 1810 samples.

Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, middle temporal gyrus, cortical plate, secondary oocyte, primordial germ cell in gonad.

Genetic regulation across tissues (GTEx eQTL / sQTL)

EXOC2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 46 tissues and its splicing (sQTL) in 23 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 69 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	1.1e-59	-0.55	6:692805:C:G
Muscle Skeletal	eqtl	6.1e-49	-0.39	6:692805:C:G
Artery Tibial	eqtl	4.8e-48	-0.50	6:692805:C:G
Whole Blood	eqtl	6.5e-37	-0.32	6:692805:C:G
Esophagus Mucosa	eqtl	3.7e-34	-0.35	6:692805:C:G
Nerve Tibial	eqtl	3.5e-31	-0.38	6:692805:C:G
Colon Transverse	eqtl	5.0e-29	-0.45	6:692805:C:G
Lung	eqtl	1.7e-28	-0.40	6:692805:C:G
Heart Atrial Appendage	eqtl	1.8e-28	+0.79	6:529104:C:T
Adipose Visceral Omentum	eqtl	3.4e-28	-0.43	6:692805:C:G
Artery Aorta	eqtl	5.7e-26	-0.40	6:692805:C:G
Esophagus Muscularis	eqtl	6.3e-26	-0.33	6:692805:C:G
Adipose Subcutaneous	eqtl	3.2e-25	-0.36	6:692805:C:G
Skin Not Sun Exposed Suprapubic	eqtl	2.1e-20	-0.33	6:694849:A:C
Heart Left Ventricle	eqtl	3.0e-20	-0.33	6:692805:C:G
Colon Sigmoid	eqtl	4.9e-18	-0.37	6:692805:C:G
Skin Sun Exposed Lower leg	eqtl	5.6e-17	-0.25	6:692805:C:G
Artery Coronary	eqtl	2.6e-16	-0.45	6:692805:C:G
Brain Spinal cord cervical c-1	eqtl	7.2e-16	-0.51	6:692805:C:G
Thyroid	eqtl	3.5e-15	-0.35	6:695411:G:A

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
71331	17.8023	1809
71330	0.3632	165
71332	0.3247	148

Top tissues by expression

showing 100 of 284 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.57	gold quality
middle temporal gyrus	UBERON:0002771	90.36	gold quality
cortical plate	UBERON:0005343	89.19	gold quality
secondary oocyte	CL:0000655	87.93	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.93	gold quality
Brodmann (1909) area 23	UBERON:0013554	87.15	gold quality
islet of Langerhans	UBERON:0000006	86.22	gold quality
oocyte	CL:0000023	86.16	gold quality
ganglionic eminence	UBERON:0004023	85.90	gold quality
calcaneal tendon	UBERON:0003701	85.53	gold quality
stromal cell of endometrium	CL:0002255	84.77	gold quality
primary visual cortex	UBERON:0002436	84.52	gold quality
granulocyte	CL:0000094	84.23	gold quality
leukocyte	CL:0000738	84.03	gold quality
monocyte	CL:0000576	83.99	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	83.91	gold quality
ventricular zone	UBERON:0003053	83.82	gold quality
mononuclear cell	CL:0000842	83.79	gold quality
colonic epithelium	UBERON:0000397	83.35	gold quality
spinal cord	UBERON:0002240	82.42	gold quality
corpus callosum	UBERON:0002336	82.33	gold quality
prefrontal cortex	UBERON:0000451	82.21	gold quality
rectum	UBERON:0001052	82.18	gold quality
testis	UBERON:0000473	82.06	gold quality
esophagus mucosa	UBERON:0002469	82.04	gold quality
mucosa of stomach	UBERON:0001199	81.96	gold quality
right testis	UBERON:0004534	81.88	gold quality
gastrocnemius	UBERON:0001388	81.84	gold quality
popliteal artery	UBERON:0002250	81.67	gold quality
tibial artery	UBERON:0007610	81.67	gold quality
esophagus	UBERON:0001043	81.66	gold quality
ectocervix	UBERON:0012249	81.61	gold quality
visceral pleura	UBERON:0002401	81.55	gold quality
muscle of leg	UBERON:0001383	81.46	gold quality
right lung	UBERON:0002167	81.44	gold quality
lymph node	UBERON:0000029	81.42	gold quality
anterior cingulate cortex	UBERON:0009835	81.35	gold quality
esophagus squamous epithelium	UBERON:0006920	81.34	gold quality
adrenal tissue	UBERON:0018303	81.33	gold quality
left testis	UBERON:0004533	81.32	gold quality
cingulate cortex	UBERON:0003027	81.24	gold quality
skin of leg	UBERON:0001511	81.23	gold quality
gall bladder	UBERON:0002110	81.21	gold quality
lower esophagus	UBERON:0013473	81.20	gold quality
lower esophagus muscularis layer	UBERON:0035833	81.19	gold quality
left coronary artery	UBERON:0001626	81.15	gold quality
lower esophagus mucosa	UBERON:0035834	81.07	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	81.05	gold quality
right adrenal gland cortex	UBERON:0035827	80.91	gold quality
aorta	UBERON:0000947	80.89	gold quality
skin of abdomen	UBERON:0001416	80.72	gold quality
occipital lobe	UBERON:0002021	80.65	gold quality
endocervix	UBERON:0000458	80.64	gold quality
neocortex	UBERON:0001950	80.54	gold quality
right coronary artery	UBERON:0001625	80.49	gold quality
right adrenal gland	UBERON:0001233	80.41	gold quality
muscle layer of sigmoid colon	UBERON:0035805	80.32	gold quality
tibial nerve	UBERON:0001323	80.31	gold quality
upper lobe of left lung	UBERON:0008952	80.29	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.23	gold quality
left adrenal gland	UBERON:0001234	80.19	gold quality
right frontal lobe	UBERON:0002810	80.15	gold quality
vagina	UBERON:0000996	80.12	gold quality
parietal pleura	UBERON:0002400	80.12	gold quality
coronary artery	UBERON:0001621	80.10	gold quality
amygdala	UBERON:0001876	80.07	gold quality
thoracic aorta	UBERON:0001515	80.03	gold quality
ascending aorta	UBERON:0001496	80.02	gold quality
omental fat pad	UBERON:0010414	80.02	gold quality
body of stomach	UBERON:0001161	80.01	gold quality
peritoneum	UBERON:0002358	79.98	gold quality
frontal cortex	UBERON:0001870	79.92	gold quality
spleen	UBERON:0002106	79.88	gold quality
adrenal gland	UBERON:0002369	79.84	gold quality
left adrenal gland cortex	UBERON:0035825	79.84	gold quality
caudate nucleus	UBERON:0001873	79.83	gold quality
pleura	UBERON:0000977	79.78	gold quality
hindlimb stylopod muscle	UBERON:0004252	79.76	gold quality
right atrium auricular region	UBERON:0006631	79.75	gold quality
stomach	UBERON:0000945	79.69	gold quality
cerebral cortex	UBERON:0000956	79.62	gold quality
tonsil	UBERON:0002372	79.60	gold quality
tibia	UBERON:0000979	79.59	gold quality
subcutaneous adipose tissue	UBERON:0002190	79.58	gold quality
adipose tissue of abdominal region	UBERON:0007808	79.56	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.50	gold quality
upper lobe of lung	UBERON:0008948	79.49	gold quality
body of uterus	UBERON:0009853	79.48	gold quality
blood	UBERON:0000178	79.45	gold quality
transverse colon	UBERON:0001157	79.44	gold quality
pancreas	UBERON:0001264	79.42	gold quality
right lobe of thyroid gland	UBERON:0001119	79.39	gold quality
nucleus accumbens	UBERON:0001882	79.38	gold quality
telencephalon	UBERON:0001893	79.37	gold quality
mucosa of transverse colon	UBERON:0004991	79.37	gold quality
placenta	UBERON:0001987	79.28	gold quality
Brodmann (1909) area 9	UBERON:0013540	79.27	gold quality
adrenal cortex	UBERON:0001235	79.21	gold quality
left lobe of thyroid gland	UBERON:0001120	79.20	gold quality
forebrain	UBERON:0001890	79.09	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.66
E-MTAB-4850	no	584.22

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 76 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Cerebellum	tissue	45.0
Cerebral cortex	tissue	38.0
Somatosensory cortex	tissue	38.0
Thalamus	tissue	36.3
Putamen	tissue	35.9
Spinal cord	tissue	35.5
Pons	tissue	35.4
Ventral forebrain	tissue	35.3
Midbrain	tissue	35.2
Superior colliculi	tissue	35.2
Occipital cortex	tissue	35.1
Septum	tissue	34.3
Hypothalamus	tissue	33.9
Hippocampal formation	tissue	33.7
Basal ganglia	tissue	33.5
Substantia nigra	tissue	33.5
Medulla oblongata	tissue	33.4
Corpus callosum	tissue	33.1
Motor cortex	tissue	32.9
Temporal cortex	tissue	31.9
Entorhinal cortex	tissue	31.0
Periaqueductal gray	tissue	31.0
Retrosplenial and cingulate cortex	tissue	30.8
Olfactory bulb	tissue	30.8
Prefrontal cortex	tissue	30.4
Insular cortex	tissue	30.3
Retrosplenial cortex	tissue	29.8
Amygdala	tissue	29.5
Locus coeruleus	tissue	29.1
Choroid plexus	tissue	26.7
Postcentral gyrus	tissue	25.3
Frontal cortex	tissue	24.7
Nucleus accumbens	tissue	22.8
Caudate putamen	tissue	22.8
Hippocampus	tissue	22.7
Thymus	tissue	17.3
Placenta	tissue	16.9
Testis	tissue	15.1
Thyroid gland	tissue	13.3
Tonsil	tissue	13.2
Lymph node	tissue	12.5
Retina	tissue	12.4
Spleen	tissue	12.3
Esophagus	tissue	11.5
Skin 1	tissue	11.1
Parathyroid gland	tissue	10.9
Appendix	tissue	10.9
Heart muscle	tissue	10.8
Lung	tissue	10.7
Breast	tissue	10.2
Urinary bladder	tissue	10.1
Tongue	tissue	9.8
Liver	tissue	9.6
Cervix	tissue	9.5
Rectum	tissue	9.4
Kidney	tissue	8.7
Vagina	tissue	8.6
Smooth muscle	tissue	8.6
Colon	tissue	8.6
Stomach 1	tissue	8.4

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Ventral spinal cord (35.5), Dorsal spinal cord (34.5), Dorsal hippocampus (33.7), White matter (33.1), Ventral hippocampus (32.4).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting EXOC2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 55 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-4470	99.66	69.35	1767
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-4753-5P	99.54	68.51	1356
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-1224-5P	99.48	65.59	803
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-542-3P	99.34	67.58	1270
HSA-MIR-4311	99.31	70.47	3041

Functional genomics

gnomAD constraint: pLI 4.27e-07, LOEUF 0.626, missense Z 2.52 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000230449 — one region, missense o/e 0.83. DepMap (CRISPR cell-line fitness): dependent in 27.1% of screened cell lines.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): MC116 (-1.191), KNS-62 (-1.107), KP-N-YS (-1.103), PEO1 (-0.994), 697 (-0.963), PCI-38 (-0.942), LS1034 (-0.94), KARPAS-422 (-0.934), SISO (-0.93), SK-N-FI (-0.924), SNU-1033 (-0.914), HCC2998 (-0.911), LS513 (-0.885), DND-41 (-0.879), A-673 (-0.876).

Literature-anchored findings (GeneRIF, showing 12)

• SEC5 has been identified as a binding partner of deafness locus putative guanine nucleotide exchange factor. (PMID:12459492)
• Functional study of the Drosophila homolog. (PMID:12575951)
• evidence that mammalian exocyst components are present as distinct subcomplexes on vesicles and the plasma membrane and that Ral GTPases regulate the assembly interface of a full octameric exocyst complex through interaction with Sec5 and Exo84 (PMID:14525976)
• These observations define the mechanistic contribution of RalGTPases to cancer cell survival and reveal the RalB/Sec5 effector complex as a component of TBK1-dependent innate immune signaling. (PMID:17018283)
• Localization of Exocyst and, by extension, targeting of Exocyst-dependent cargo, is dependent on Ral GTPases, which control association between Sec5 and paxillin. (PMID:18697830)
• shRNA-mediated knockdown of the Ral effector proteins Sec5 and Exo84, but less so in the case of RalBP1, reduced oncogenic RalGEF-mediated transformation and oncogenic Ras-driven tumorigenic growth of human cells. (PMID:20145037)
• Data show that Mc1R, HERC2, IRF4, TYR and EXOC2 are ranked highest in hair color prediction analysis. (PMID:21197618)
• We identified interactions between RalA and its effectors sec5 and exo84 in the Exocyst complex as directly necessary for migration and invasion of prostate cancer tumor cells. (PMID:22761837)
• Exocyst sec5 regulates exocytosis of newcomer insulin granules underlying biphasic insulin secretion. (PMID:23844030)
• data suggest that the induction of SGK1 through treatment with dexamethasone alters MT dynamics to increase Sec5-GEF-H1 interactions, which promote GEF-H1 targeting to adhesion sites. (PMID:26359301)
• Mutations in the exocyst component EXOC2 cause severe defects in human brain development. (PMID:32639540)
• The exocyst subunit EXOC2 regulates the toxicity of expanded GGGGCC repeats in C9ORF72-ALS/FTD. (PMID:38935506)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	exoc2	ENSDARG00000055610
mus_musculus	Exoc2	ENSMUSG00000021357
rattus_norvegicus	Exoc2	ENSRNOG00000060266
drosophila_melanogaster	Sec5	FBGN0266670
caenorhabditis_elegans		WBGENE00004752

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1913732) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 4 distinct phenotype terms.

Mouse phenotype (MP)	Records
failure of blastocyst to hatch from the zona pellucida	1
preweaning lethality, complete penetrance	1
embryonic lethality prior to organogenesis	1
embryonic lethality prior to organogenesis, complete penetrance	1

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
HUS1B	protein-coding	135458
IRF4	protein-coding	3662
LINC01622	ncRNA	285768
LIRIL2R	ncRNA	105374869
LINC03066	ncRNA	285766
DUSP22	protein-coding	56940

Protein

Protein identifiers

Exocyst complex component 2 — Q96KP1 (reviewed: Q96KP1)

Alternative names: Exocyst complex component Sec5

All UniProt accessions (2): Q96KP1, Q2MDF5

UniProt curated annotations — full annotation on UniProt →

Function. Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane.

Subunit / interactions. The exocyst complex is composed of EXOC1, EXOC2, EXOC3, EXOC4, EXOC5, EXOC6, EXOC7 and EXOC8. Interacts with EXOC3L1. Interacts with GNEFR/DELGEF; this interaction occurs only in the presence of magnesium or manganese and is stimulated by dCTP or GTP. Interacts with RALA and RALB. Interacts with ARL13B; regulates ARL13B localization to the cilium membrane.

Subcellular location. Midbody. Midbody ring.

Tissue specificity. Widely expressed with highest levels in brain and placenta.

Disease relevance. Neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia (NEDFACH) [MIM:619306] An autosomal recessive disorder characterized by global developmental delay, intellectual disability, facial dysmorphism, and abnormalities of the cerebellum observed on brain imaging. Disease severity is variable. Some affected individuals have poor overall growth with microcephaly, delayed walking, spasticity, and poor or absent speech. Others may achieve more significant developmental milestones. Additional variable manifestations may include cardiac ventricular septal defect, spasticity, cataracts, optic nerve hypoplasia, seizures, and joint contractures. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. Interacts with RALA through the TIG domain.

Similarity. Belongs to the SEC5 family.

RefSeq proteins (1): NP_060773* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002909	IPT_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR014756	Ig_E-set	Homologous_superfamily
IPR029175	EXOC2/Sec5	Family
IPR039481	EXOC2/Sec5_N_dom	Domain

Pfam: PF01833, PF15469

UniProt features (16 total): modified residue 6, sequence variant 4, sequence conflict 2, chain 1, domain 1, mutagenesis site 1, coiled-coil region 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96KP1-F1	80.82	0.46

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Predicted intracellular proteins, RAS pathway related proteins, Disease related genes, Potential drug targets, Human disease related genes, Congenital malformations, Congenital malformations of the nervous system, Essential proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles

Antibody reliability (HPA): IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6)

Type	Positions
Phosphoserine	431, 432, 435, 888
Phosphothreonine	440
N6-acetyllysine	454

Mutagenesis-validated functional residues (1)

Position	Phenotype
11	impaired cytokinesis. loss of rala-binding. no change in localization to the midbody during cytokinesis.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 10; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

10 pathways:

ID	Pathway	Evidence
R-HSA-264876	Insulin processing	curated
R-HSA-5620916	VxPx cargo-targeting to cilium	curated
R-HSA-5620920	Cargo trafficking to the periciliary membrane	—
R-HSA-5617833	Cilium Assembly	—
R-HSA-199991	Membrane Trafficking	—
R-HSA-392499	Metabolism of proteins	—
R-HSA-1852241	Organelle biogenesis and maintenance	—
R-HSA-2980736	Peptide hormone metabolism	—
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane	electronic
R-HSA-5653656	Vesicle-mediated transport	—

MSigDB gene sets: 249 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GOBP_MITOTIC_CYTOKINESIS, GOBP_VESICLE_LOCALIZATION, GOBP_VESICLE_TARGETING, CAFFAREL_RESPONSE_TO_THC_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOMF_GTPASE_BINDING, GOBP_MEMBRANE_DOCKING, chr6p25, GOBP_EXOCYTOSIS, GOBP_GOLGI_TO_PLASMA_MEMBRANE_TRANSPORT, MODULE_205, GOBP_VESICLE_DOCKING_INVOLVED_IN_EXOCYTOSIS

GO Biological Process (6): mitotic cytokinesis (GO:0000281), exocytosis (GO:0006887), Golgi to plasma membrane transport (GO:0006893), protein transport (GO:0015031), membrane fission (GO:0090148), regulation of entry of bacterium into host cell (GO:2000535)

GO Molecular Function (4): protein kinase binding (GO:0019901), GTP-dependent protein binding (GO:0030742), small GTPase binding (GO:0031267), protein binding (GO:0005515)

GO Cellular Component (5): exocyst (GO:0000145), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020), Flemming body (GO:0090543)

Reactome top-level categories

7 top-level categories:

Category	Pathways
Membrane Trafficking	1
Peptide hormone metabolism	1
Cargo trafficking to the periciliary membrane	1
Vesicle-mediated transport	1
Metabolism of proteins	1
Organelle biogenesis and maintenance	1
Assembly of the 9+0 primary cilium	1

GO top-level categories

25 GO namespaces:

Category	Terms
cellular anatomical structure	3
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
post-Golgi vesicle-mediated transport	1
vesicle-mediated transport to the plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
membrane organization	1
entry of bacterium into host cell	1
modulation by symbiont of entry into host	1
kinase binding	1
protein binding	1
GTPase binding	1
binding	1
cell cortex	1
vesicle tethering complex	1
cytoplasm	1
membrane	1
cell periphery	1
midbody	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 17 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
Golgi to plasma membrane transport	BP	mutant phenotype
regulation of entry of bacterium into host cell	BP	mutant phenotype
exocyst	CC	direct assay
membrane	CC	high-throughput assay
protein kinase binding	MF	physical interaction
small GTPase binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 1,536 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EXOC2	RALB	P11234	927
EXOC2	EXOC8	Q8IYI6	923
EXOC2	EXOC1	Q9NV70	922
EXOC2	EXOC5	O00471	921
EXOC2	EXOC3	O60645	921
EXOC2	EXOC4	Q96A65	921
EXOC2	EXOC7	Q9UPT5	920
EXOC2	EXOC6	Q8TAG9	917
EXOC2	SERGEF	Q9UGK8	799
EXOC2	DPH3	Q96FX2	774
EXOC2	TBK1	Q9UHD2	772
EXOC2	RALA	P11233	752
EXOC2	SSR2	P43308	697
EXOC2	RALBP1	Q15311	649
EXOC2	IKBKE	Q14164	623

IntAct

Human interaction partners of EXOC2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

14 partners by confidence:

Partner	Interaction type	MIscore	Records
EXOC1	direct interaction	0.880	5
EXOC3	association	0.790	2
EGFR	physical association	0.400	1
SERGEF	physical association	0.400	1
CDKN2A	physical association	0.370	1
ESX1	physical association	0.370	1
DISC1	physical association	0.000	1
EXOC4	physical association	0.000	1
EXOC5	physical association	0.000	1
EXOC6	physical association	0.000	1
EXOC6B	physical association	0.000	1
EXOC7	physical association	0.000	1
EXOC8	physical association	0.000	1
RALB	physical association	0.000	1

BioGRID (180 interactions; top human partners by supporting records): EXOC8 (Co-fractionation; 10 records), RALB (Affinity Capture-MS; 8 records), EXOC3 (Co-fractionation; 7 records), EXOC4 (Co-fractionation; 7 records), EXOC6 (Co-fractionation; 6 records), RALA (Co-crystal Structure; 6 records), EXOC1 (Co-fractionation; 5 records), EXOC5 (Co-fractionation; 4 records), EXOC7 (Co-fractionation; 4 records), BECN1 (Affinity Capture-Western; 3 records), BSG (Affinity Capture-MS; 3 records), APLNR (Affinity Capture-MS; 2 records), CHRM3 (Affinity Capture-MS; 2 records), EDNRB (Affinity Capture-MS; 2 records), EXOC6B (Affinity Capture-MS; 2 records)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
EXOC2	“form complex”	“Exocyst_EXOC6B variant”	binding
EXOC2	“form complex”	“Exocyst_EXOC6 variant”	binding

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
Exocyst complex	8	EXOC1, EXOC2, EXOC3, EXOC4, EXOC5, EXOC6, EXOC7, EXOC8

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 14 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VxPx cargo-targeting to cilium	7	363.4×	4e-16
Insulin processing	7	319.8×	6e-16
Translocation of SLC2A4 (GLUT4) to the plasma membrane	7	108.0×	1e-12

GO biological processes:

GO term	Partners	Fold	FDR
Golgi to plasma membrane transport	6	240.7×	2e-12
membrane fission	8	234.9×	1e-16
mitotic cytokinesis	8	148.2×	4e-15
exocytosis	8	86.8×	3e-13

Disease & clinical

Genetic variants

Variant evidence for EXOC2: 252 ClinVar records (4 pathogenic / likely pathogenic); 61 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

252 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	181
Likely benign	25
Benign	9

Top pathogenic / likely-pathogenic (4)

Showing all 4 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
2506536	GRCh37/hg19 6p25.3(chr6:491126-1624775)	Pathogenic	criteria provided, single submitter	1
2685193	GRCh37/hg19 6p25.3(chr6:647204-1716710)x1	Pathogenic	criteria provided, single submitter	1
1074298	NM_018303.6(EXOC2):c.1739T>C (p.Leu580Ser)	Pathogenic	no assertion criteria provided	1
443497	GRCh37/hg19 6p25.3-q27(chr6:156975-170919482)	Pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore EXOC2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 30 predictions of 3,502):

Position(s)	Effect	Δscore	Sites
6:491123–491124	donor_loss	1.0000	4
6:497365–497366	donor_loss	1.0000	4
6:497495	acceptor_gain	1.0000
6:499701–499702	acceptor_loss	1.0000	6
6:499707	acceptor_gain	1.0000
6:532468	donor_loss	1.0000
6:532611–532612	acceptor_loss	1.0000	6
6:549173–549174	donor_loss	1.0000	5
6:553927	acceptor_gain	1.0000
6:564544	donor_loss	1.0000

AlphaMissense

2,074 missense substitutions predicted likely pathogenic (of 6,088 scored), across 561 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F284	8	0.991	0.999
F321	8	0.989	0.998
D305	8	0.988	0.998
F282	8	0.985	1.000
F313	8	0.974	0.997
F257	8	0.969	0.998
F165	8	0.960	0.997
D268	8	0.953	0.996
F90	8	0.948	0.997
D300	8	0.943	0.989
D368	8	0.943	0.992
F466	8	0.915	0.993
D37	8	0.908	0.965
D265	8	0.898	0.985
F502	8	0.894	0.982
F213	8	0.889	0.971
F451	8	0.875	0.978
F212	8	0.872	0.991
N293	8	0.867	0.993
D217	8	0.863	0.970

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	1.11e-05

Disease associations

OMIM: gene MIM:615329 | disease phenotypes: MIM:619306

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia	Moderate	Autosomal recessive	2

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (4 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

4 panels:

Panel	Rating
Hypotonic infant	amber
Intellectual disability	amber
Leukodystrophy, childhood onset	amber
Paediatric disorders	amber

Mondo (1): neurodevelopmental disorder with dysmorphic facies and cerebellar hypoplasia (MONDO:0859141)

HPO phenotypes

37 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000219	Thin upper lip vermilion
HP:0000300	Oval face
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000340	Sloping forehead
HP:0000343	Long philtrum
HP:0000369	Low-set ears
HP:0000431	Wide nasal bridge
HP:0000437	Depressed nasal tip
HP:0000582	Upslanted palpebral fissure
HP:0000958	Dry skin
HP:0001250	Seizure
HP:0001320	Cerebellar vermis hypoplasia
HP:0001321	Cerebellar hypoplasia
HP:0001371	Flexion contracture
HP:0001629	Ventricular septal defect
HP:0001747	Accessory spleen
HP:0002079	Hypoplasia of the corpus callosum
HP:0002198	Dilated fourth ventricle
HP:0002263	Exaggerated cupid’s bow
HP:0002365	Hypoplasia of the brainstem
HP:0002419	Molar tooth sign on MRI
HP:0002510	Spastic tetraplegia
HP:0002870	Obstructive sleep apnea
HP:0003429	CNS hypomyelination
HP:0003577	Congenital onset
HP:0003593	Infantile onset
HP:0005484	Secondary microcephaly
HP:0006610	Wide intermamillary distance
HP:0007766	Optic disc hypoplasia
HP:0010664	Fusion of the left and right thalami
HP:0011344	Severe global developmental delay
HP:0020206	Simple ear
HP:0025386	Bitemporal hollowing
HP:0030724	Central nervous system cyst
HP:0031913	Rhombencephalosynapsis

GWAS associations

showing 30 of 61 associations:

Study	Trait	p-value
GCST006988_15	Blond vs. brown/black hair color	2e-59
GCST006982_1	Waldenström macroglobulinemia / lymphoplasmacytic lymphoma	1e-54
GCST003726_3	Basal cell carcinoma	1e-51
GCST90013410_44	Basal cell carcinoma	1e-23
GCST006989_29	Brown vs. black hair color	8e-22
GCST002636_2	Diffuse large B cell lymphoma	2e-21
GCST90013410_45	Basal cell carcinoma	4e-21
GCST004606_97	Eosinophil count	5e-21
GCST90002381_112	Eosinophil count	6e-20
GCST004624_104	Sum eosinophil basophil counts	4e-19
GCST000119_1	Freckles	4e-18
GCST004600_167	Eosinophil percentage of white cells	8e-18
GCST90002381_110	Eosinophil count	1e-17
GCST004617_94	Eosinophil percentage of granulocytes	4e-17
GCST004623_76	Neutrophil percentage of granulocytes	7e-16
GCST006412_100	Intraocular pressure	1e-15
GCST006065_33	Glaucoma (primary open-angle)	2e-15
GCST90002382_193	Eosinophil percentage of white cells	4e-14
GCST000371_4	Tanning	5e-14
GCST90002382_464	Eosinophil percentage of white cells	7e-14
GCST004142_23	Melanoma	9e-14
GCST007896_1	Primary central nervous system lymphoma	2e-13
GCST90002381_111	Eosinophil count	2e-13
GCST005580_280	Intraocular pressure	3e-12
GCST006394_83	Intraocular pressure	3e-12
GCST90011766_4	Glaucoma (primary open-angle)	1e-11
GCST005527_25	Psoriasis	2e-11
GCST005580_211	Intraocular pressure	4e-11
GCST009725_91	Intraocular pressure	5e-11
GCST009724_27	Vertical cup-disc ratio (multi-trait analysis)	6e-11

EFO canonical traits (from GWAS)

12 canonical traits:

EFO ID	Trait name
EFO:0003963	freckles
EFO:0003924	hair color
EFO:0004279	suntan
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004842	eosinophil count
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0005090	basophil count
EFO:1001017	limited scleroderma
EFO:0004695	intraocular pressure measurement
EFO:0009944	Antiglaucoma preparations and miotics use measurement
EFO:0006939	cup-to-disc ratio measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, affects methylation	4
bisphenol A	affects cotreatment, increases methylation, increases expression	2
Cadmium	decreases expression, increases expression, decreases reaction	2
Particulate Matter	affects cotreatment, decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
decabromobiphenyl ether	increases expression	1
kojic acid	increases expression	1
arsenite	affects binding, decreases reaction	1
butyraldehyde	decreases expression	1
tetrabromobisphenol A	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
nickel sulfate	increases expression	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	increases expression	1
asparanin A	decreases expression	1
bisphenol S	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects methylation	1
Vehicle Emissions	increases abundance, increases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A9N7	GIST-R5	Cancer cell line
CVCL_B1RN	Abcam HeLa EXOC2 KO	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00029224	Phase 4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	Phase 4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	Phase 4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	Phase 4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	Phase 4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	Phase 4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	Phase 4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	Phase 4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	Phase 4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	Phase 4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	Phase 4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	Phase 4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	Phase 4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	Phase 4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	Phase 4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	Phase 4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	Phase 4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	Phase 4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	Phase 4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	Phase 4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	Phase 4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	Phase 4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	Phase 4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	Phase 4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	Phase 4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	Phase 4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	Phase 4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	Phase 4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	Phase 4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	Phase 4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	Phase 4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	Phase 4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	Phase 4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	Phase 4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	Phase 4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	Phase 4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	Phase 4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	Phase 4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	Phase 4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	Phase 4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
NCT01673984	Phase 4	TERMINATED	GP Extended Action Triptorelin
NCT01753297	Phase 4	COMPLETED	A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
NCT01794793	Phase 4	COMPLETED	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
NCT01950871	Phase 4	TERMINATED	Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning
NCT01995513	Phase 4	COMPLETED	Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
NCT02102646	Phase 4	COMPLETED	MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism
NCT02116582	Phase 4	COMPLETED	A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer
NCT02149628	Phase 4	COMPLETED	The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide
NCT02405858	Phase 4	COMPLETED	A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
NCT02441517	Phase 4	TERMINATED	A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441894	Phase 4	COMPLETED	Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer
NCT02475057	Phase 4	COMPLETED	Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
NCT02511665	Phase 4	UNKNOWN	Metformin And Longevity
NCT02651948	Phase 4	COMPLETED	Transperineal, MRI-guided, Prostate Biopsy
NCT02721433	Phase 4	COMPLETED	4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases
NCT02726009	Phase 4	COMPLETED	A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
NCT02749825	Phase 4	TERMINATED	Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
NCT02757365	Phase 4	UNKNOWN	Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer
NCT02773251	Phase 4	COMPLETED	The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery
NCT02812186	Phase 4	COMPLETED	Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery